ERBB2 and breast cancer: Oliveras-Ferraros et al. provided experimental evidence that EMT features in CTCs isolated from basal-like breast cancer patients recognize a new subgroup of HER2 gene-amplified breast carcinomas with primary resistance to HER2-targeted therapies, such as trastuzumab [40].